Lyell Immunopharma, Inc.
LYEL
$22.31
$1.507.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.65% | -57.61% | -46.50% | -46.18% | -7.31% |
| Total Depreciation and Amortization | -27.94% | -18.94% | -10.86% | -3.06% | -2.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 423.85% | 381.34% | 241.94% | 247.15% | -37.86% |
| Change in Net Operating Assets | -635.47% | -21,665.12% | -309.94% | -191.20% | 96.57% |
| Cash from Operations | -5.92% | -8.24% | -9.79% | 0.79% | 4.62% |
| Capital Expenditure | -16.85% | 11.02% | 42.52% | 82.73% | 93.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 644.50% | 154.49% | 15.34% | -17.40% | -109.25% |
| Cash from Investing | 537.40% | 108.44% | -2.30% | -33.48% | -109.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,640.71% | -67.64% | -43.60% | -36.27% | -18.81% |
| Repurchase of Common Stock | 100.00% | 100.00% | 100.00% | 83.37% | 53.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,971.66% | -58.74% | -29.31% | -23.92% | -10.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.22% | 63.36% | -124.15% | -274.88% | -209.42% |